Company: Global Genomics Group
Job title: Founder & CEO
Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and serial entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing novel drugs, nutraceuticals and blood-based biomarkers for common, chronic diseases, as well as for prevention, wellness and healthy longevity. G3’s deep discovery platform is predicated on deep phenotyping, deep molecular profiling and deep learning. G3 has developed and patented a diagnostic blood test for cardiovascular disease and has identified and is developing several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute, where he utilized a combination of non-invasive imaging, blood-based biomarkers and genomics for cardiovascular prevention and wellness. Voros was also a critical participant in the discovery, validation, development and commercialization of a blood-based gene expression test for cardiovascular disease called “CorusCAD”, which was featured as #7 on Time Magazine’s “Top Ten of Everything” in 2010. Voros has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.